Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03107884 · ClinicalTrials.gov registry record · Early Phase 1

Role of Metformin on Muscle Health of Older Adults

A Early Phase 1 study of Insulin Resistance and Muscle Atrophy, sponsored by University of Utah.

Active
Registry status
Early Phase 1
Development phase
64
Enrollment target
1
Study location

NCT03107884: Active Early Phase 1 study of Insulin Resistance and Muscle Atrophy, sponsored by University of Utah.

NCT03107884 is a Early Phase 1 study of Insulin Resistance and Muscle Atrophy that is active but no longer recruiting, run by University of Utah. The registered enrollment target is 64 participants, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03107884, a Early Phase 1 study of Insulin Resistance and Muscle Atrophy, is active but no longer recruiting, sponsored by University of Utah.

ACTIVE NOT RECRUITING
Registry status
Early Phase 1
Development phase
64 participants
Enrollment target
1
Study location

Study Summary

Muscle atrophy and insulin resistance are common after bed rest in healthy older adults. Metformin treatment has been shown to improve insulin sensitivity and attenuate muscle loss in insulin resistance adults though the mechanisms are not fully known. Metformin used as a preventive strategy to maintain muscle and metabolic health in bed ridden older adults has not been investigated.

Primary Outcome

Change in muscle size from baseline to 5-days of bed rest (determined from MRI)

Interventions

  • DRUG Metformin (Bed Rest)
  • DRUG Placebo (Bed Rest)
  • DRUG Metformin (2 week run-in only)
  • DRUG Placebo (2 week run-in only)

Study Locations (1)

Utah

  • University of Utah - Salt Lake City

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2019-08-01
Est. Completion 2026-11-01
Phase Early Phase 1
University of Utah

818 total trials

What the registry record for NCT03107884 still lists

NCT03107884 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (74% lower).

The record links to 2 conditions, with Insulin Resistance appearing as the primary indexed condition, and to 4 interventions - of which Metformin (Bed Rest) is the first listed.

NCT03107884 reports a single indexed study location in Utah.

Frequently Asked Questions

What is clinical trial NCT03107884 about?

NCT03107884 is a clinical study titled "Role of Metformin on Muscle Health of Older Adults". Muscle atrophy and insulin resistance are common after bed rest in healthy older adults. Metformin treatment has been shown to improve insulin sensitivity and attenuate muscle loss in insulin resistance adults though the mechanisms are not fully known. Metformin used as a preventive strategy to main...

What is the current status of trial NCT03107884?

This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 64 participants. The study started on 2019-08-01. Estimated completion is 2026-11-01.

What conditions does trial NCT03107884 study?

This clinical trial studies the following conditions: Insulin Resistance, Muscle Atrophy.

What interventions are being tested in trial NCT03107884?

The interventions under investigation include: Metformin (Bed Rest) (DRUG), Placebo (Bed Rest) (DRUG), Metformin (2 week run-in only) (DRUG), Placebo (2 week run-in only) (DRUG).

Who is sponsoring clinical trial NCT03107884?

This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03107884 being conducted?

This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Insulin Resistance

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03107884's enrollment target sits among peer trials

64 44th of 120 higher than 77 of 120 other Insulin Resistance trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Insulin Resistance trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01853631 · 64 participants · Phase 1

    Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

  • NCT03739502 · 64 participants · Phase 2

    A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant

  • NCT03739814 · 64 participants · Phase 2

    Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • NCT03866408 · 64 participants · Early Phase 1

    Insulin Regulation of Lipolysis and Lipolysis Proteins

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03107884, the US trial registry maintained by the National Library of Medicine. NCT03107884 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.